Advertisement
Advertisement
U.S. markets open in 2 hours 21 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Ipsen S.A. (IPSEY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
23.51-0.10 (-0.42%)
At close: 02:50PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close23.61
Open23.51
Bid0.00 x 0
Ask0.00 x 0
Day's Range23.51 - 23.51
52 Week Range21.17 - 32.51
Volume535
Avg. Volume948
Market Cap7.762B
Beta (5Y Monthly)0.85
PE Ratio (TTM)10.45
EPS (TTM)2.25
Earnings DateN/A
Forward Dividend & Yield0.32 (1.37%)
Ex-Dividend DateMay 31, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for IPSEY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • IPSEN SA SPONS ADR EA REPR 0.25
    Analyst Report: MERCK Kommanditgesellschaft auf AktienMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (46% of 2021 sales) provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (36%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Business Wire

    Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022

    PARIS, August 05, 2022--Regulatory News: Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-

  • Benzinga

    Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure

    Merrimack Pharmaceuticals Inc's (NASDAQ: MACK) partner announced that Ipsen SA (OTC: IPSEY) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study did not meet the primary endpoint of overall survival in patients treated with Onivyde versus topotecan. However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed. The safety and tolerabilit

  • Business Wire

    Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

    PARIS, August 03, 2022--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III RESILIENT trial did not meet its primary endpoint of overall survival (OS) compared to topotecan. The trial is evaluating Onivyde® (irinotecan liposomal injection) versus topotecan in patients with small cell lung cancer (SCLC), who have progressed on or after platinum-based first-line therapy treatment. RESILIENT is a Phase III trial conducted in two parts; the first part read out in 20

Advertisement
Advertisement